XSHE
002873
Market cap297mUSD
Oct 09, Last price
8.55CNY
1D
0.94%
1Q
11.33%
IPO
-2.30%
Name
Guiyang Xintian Pharmaceutical Co Ltd
Chart & performance
P/E
220.80
P/S
2.68
EPS
0.04
Div yield, %
1.18%
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
-5.02%
Revenues
750m
-12.57%
Net income
9m
-82.59%
CFO
84m
-4.99%
Dividend
May 27, 20260.03 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guiyang Xintian Pharmaceutical Co.,Ltd. is a Chinese company dedicated to the research, development, production, and commercialization of traditional Chinese medicines (TCMs) for a wide range of ailments. Its product offerings include various pharmaceutical formulations such as hard capsules, gels, mixtures, granules, and tablets. These medicines are specifically designed to treat diverse medical conditions, including antitumor applications, gynecological issues, urinary tract problems, breast and thyroid disorders, blood-related illnesses, heat-related syndromes, oral health complaints, common colds, and cardiovascular diseases. The company was founded in 1995 and is headquartered in Guiyang, China.
Key people
Zhihui Zeng
Chief Financial Officer · since 2019
Yuyou Chen
Deputy General Manager · since 2017
Maochen Wei
Deputy General Manager · since 2016
Dalun Dong
Director · since 2022
Zhonglei He
Director · since 2022
Weijia Ji
Director · since 2022
Wenyi Wang
Director · since 2022
Jinhua Wang
Director · since 2022
Guangping Wang
Director · since 2022
Independent Director · since 2023
Feng Guan
Independent Director · since 2021
Feng Guan
Independent Director · since 2022
Jianguang Luo
Independent Director · since 2017
Jie Zhang
Independent Director · since 2022
Jie Zhang
Independent Director · since 2021
Headquarters & legal address
贵州省贵阳市贵阳国家高新技术产业开发区新添大道114号
贵阳市, GZ 550000
CN
贵阳市, GZ 550000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||